High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging

Sha Lou, Benjamin Balluff, Marieke A. de Graaff, Arjen H. G. Cleven, Inge Briaire-de Bruijn, Judith V. M. G. Bovee, Liam A. McDonnell*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Web of Science)

Abstract

The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high-grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDIMSI of proteins to distinguish between high-grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (N-total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors (p
Original languageEnglish
Pages (from-to)1802-1813
JournalProteomics
Volume16
Issue number11-12
DOIs
Publication statusPublished - Jun 2016

Keywords

  • Biomarker discovery
  • Biomedicine
  • Intratumor heterogeneity
  • Mass spectrometry imaging
  • Soft tissue sarcoma

Cite this